OTCMKTS:EMMA Emmaus Life Sciences (EMMA) Stock Price, News & Analysis $0.04 -0.02 (-29.02%) As of 10/9/2026 02:19 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Emmaus Life Sciences Stock (OTCMKTS:EMMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Emmaus Life Sciences alerts:Sign Up Key Stats Today's Range$0.04▼$0.0550-Day Range$0.01▼$0.0852-Week Range$0.01▼$0.09Volume26,055 shsAverage Volume32,110 shsMarket Capitalization$3.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Emmaus Life Sciences, Inc. is a biopharmaceutical company focused primarily on developing and commercializing treatments for rare and serious diseases. The company’s best-known product is Endari (L-glutamine), an oral powder approved by the U.S. Food and Drug Administration to reduce the acute complications of sickle cell disease in adults and children aged five and older. Historically, Emmaus has concentrated on therapies for sickle cell disease and other conditions with significant unmet medical needs. Its activities have included product development, regulatory submissions, manufacturing, and commercialization, with Endari serving as its principal marketed therapy. The company has also investigated additional applications for L-glutamine and other potential treatments. Emmaus Life Sciences has been based in California and has served the U.S. market through its pharmaceutical operations. Publicly available information about the company’s current operations and leadership is limited, so details regarding its present management structure and geographic reach may have changed.AI Generated. May Contain Errors. Read More Receive EMMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EMMA Stock News HeadlinesEmmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic CancerAugust 31, 2026 | businesswire.comEmmaus Life Sciences Reports Quarterly Financial ResultsMay 15, 2026 | businesswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 11 at 1:00 AM | Base Camp Trading (Ad)Emmaus Life Sciences Reports Annual Financial ResultsMarch 30, 2026 | businesswire.comEmmaus Life Sciences grants NeoImmuneTech Endari distribution rightsDecember 31, 2025 | msn.comEmmaus Life Sciences enters license, distribution agreement with NeoImmuneTechDecember 31, 2025 | msn.comEmmaus, NIT sign Endari distribution agreementDecember 31, 2025 | finance.yahoo.comEmmaus Life Sciences restructures convertible debt via exchangeDecember 22, 2025 | tipranks.comSee More Headlines EMMA Stock Analysis - Frequently Asked Questions How have EMMA shares performed this year? Emmaus Life Sciences' stock was trading at $0.0130 at the beginning of 2026. Since then, EMMA shares have increased by 229.2% and is now trading at $0.0428. How were Emmaus Life Sciences' earnings last quarter? Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) issued its earnings results on Friday, August, 14th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $6.32 million for the quarter. How do I buy shares of Emmaus Life Sciences? Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emmaus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Matinas Biopharma (MTNB), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM) and Company Calendar Last Earnings8/14/2026Today10/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:EMMA CIK822370 Webwww.emmausmedical.com Phone(310) 214-0065Fax866-294-2611Employees33Year Founded2000Profitability EPS (Trailing Twelve Months)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.49 million Net Margins-38.78% Pretax Margin-34.93% Return on EquityN/A Return on Assets-31.18% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.07 Sales & Book Value Annual Sales$12.45 million Price / Sales0.24 Cash FlowN/A Price / Cash FlowN/A Book Value($0.91) per share Price / Book-0.05Miscellaneous Outstanding Shares70,190,000Free Float45,622,000Market Cap$3.00 million OptionableNot Optionable Beta9.73 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:EMMA) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emmaus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emmaus Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EMMA Stock Alerts